Literature DB >> 28486340

Why a universal antiretroviral regimen?

Charles W Flexner1, Polly Clayden, Willem D F Venter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28486340      PMCID： PMC5722220          DOI： 10.1097/COH.0000000000000390

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN： 1746-630X            Impact factor:   4.283


× No keyword cloud information.
  16 in total

Review 1.  Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide.

Authors:  Dzintars Gotham; Andrew Hill; Anton L Pozniak
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

Review 2.  Can the generic antiretroviral industry support access to a universal antiretroviral regimen?

Authors:  Carolyn D Amole; Caroline Middlecote; Vineet R Prabhu; N Kumarasamy
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

Review 3.  The role of activists in access to HIV and tuberculosis treatment and prevention.

Authors:  Nathan Geffen
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

Review 4.  Dealing with large-scale supply lines when introducing new regimens.

Authors:  Christine Malati; Joshua Rosenfeld; Sherif Mowafy; Trevor Rittmiller; Joel Kuritsky; John Crowley
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

5.  Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice.

Authors:  Mark G J de Boer; Guido E L van den Berk; Natasja van Holten; Josephine E Oryszcyn; Willemien Dorama; Daoud Ait Moha; Kees Brinkman
Journal:  AIDS       Date:  2016-11-28       Impact factor: 4.177

Review 6.  Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.

Authors:  Jeffrey M Jacobson; Charles W Flexner
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

Review 7.  A cost-savings analysis of a candidate universal antiretroviral regimen.

Authors:  David Ripin; Vineet R Prabhu
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

Review 8.  Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable?

Authors:  Nathan Ford; Marco Vitoria; Meg Doherty; Andy Gray
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

Review 9.  Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries.

Authors:  Kay Seden; Marta Boffito; Saye Khoo
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

Review 10.  When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.

Authors:  Marco Vitoria; Nathan Ford; Polly Clayden; Anton L Pozniak; Andrew M Hill
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283
View more
  3 in total

Review 1.  Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.

Authors:  Amy L Slogrove; Polly Clayden; Elaine J Abrams
Journal:  Curr Opin HIV AIDS       Date:  2017-07       Impact factor: 4.283

2.  Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration.

Authors:  Elaine J Abrams; Jintanat Ananworanich; Moherndran Archary; McNeil Ngongondo; Pim Brouwers
Journal:  J Acquir Immune Defic Syndr       Date:  2018-08-15       Impact factor: 3.731

3.  Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?

Authors:  Lee Fairlie; Catriona Waitt; Shahin Lockman; Michelle Moorhouse; Elaine J Abrams; Polly Clayden; Marta Boffito; Saye Khoo; Helen Rees; Amandine Cournil; Willem Francois Venter; Celicia Serenata; Matthew Chersich
Journal:  J Int AIDS Soc       Date:  2019-09       Impact factor: 5.396
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.